ClinicalTrials.gg
RecruitingNCT05657678NephroDUpdated Apr 23, 2024

Vitamin D3 Supplementation in Critically Ill Patients Undergoing CRRT

A Phase 4 interventional study of Vitamin D3 - 750 000 IU and Vitamin D3 - 500 000 IU in Vitamin D3 Deficiency, sponsored by Uniwersytecki Szpital Kliniczny w Opolu. Recruiting at 4 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Uniwersytecki Szpital Kliniczny w Opolu · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients hospitalized in intensive care units (ICU) are particularly susceptible to vitamin D3 deficiencies. This can be due to the severity of their underlying disease, the type of treatment they are on, malnutrition before and inadequate nutrition during the hospitalisation preceding ICU admission, as well as advanced age. It has also been established that plasma levels of 25(OH)D3 tend to systematically decrease during ICU treatment. Therapeutic interventions administered in ICU settings such as fluid resuscitation or extracorporeal therapies can cause additional vitamin D3 deficiencies. The incidence of deficiency in critically ill patients can reach up to 90%, and even 30% of ICU patients can have undetectable plasma levels. It is impossible to replenish vitamin D3 levels in critically ill patients with traditional enteral and parenteral nutrition treatment regimens, because nutritional products contain too little of the vitamin. Vitamin D3 deficiency in critically ill patients has been associated with acute kidney injury, acute respiratory failure, sepsis, septic shock and increased all-cause ICU mortality. Despite that, assessment of plasma 25(OH)D3 levels is not a routine practice in ICUs. In view of the prevalence of vitamin D3 deficiencies in ICU patients, rapid replenishment of this deficiency with an increased supplementation dose should be considered as a potential means to improve prognosis in this patient population. The current standard therapy is the administration of 500,000 IU of vitamin D3 via the enteral route in ICU patients with severe deficiency (recommended by ESPEN). The NephroD study is meant to help answer the question whether increasing the standard ICU supplementation dose of vitamin D3 by 50% will ensure a more effective replenishment of this vitamin in critically ill patients undergoing CRRT.

02

Conditions studied

  • Vitamin D3 Deficiency

Keywords

  • vitamin D
  • severe deficiency
  • continuous renal replacement therapy
  • intensive care
  • supplementation
03

In context

Lead sponsor

Uniwersytecki Szpital Kliniczny w Opolu is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of the following indications for initiation of CRRT with CVVHDF or CVVHF (acc. to KDIGO, Clinical Practice Guideline for Acute Kidney Injury):

    • replacement of kidney function in acute kidney injury
    • hyperkalaemia
    • metabolic acidosis
    • pulmonary oedema
    • uraemic complications (bleeding disorder, pericarditis)
    • hypervolaemia
    • support of renal function (volume control, regulation of acid-base and electrolyte status)
  2. Sequential Organ Failure Assessment (SOFA) score of minimum 5 points at enrolment
  3. Age of >18 years
  4. Plasma 25(OH)D3 levels ≤12.5 ng/ml as measured by the local laboratory of a participating hospital
  5. Properly managed enteral nutrition regardless of dosing

Exclusion criteria

Exclusion Criteria:

  1. Acute or advanced chronic liver failure (estimated on the basis of the clinical picture and biochemical markers: plasma , plasma and ALT, high plasma AST/ALT ratio, glycaemia, )
  2. Hypercalcaemia (total calcium concentration >11 mg/dl)
  3. Any parathyroid disorder
  4. End stage renal disease according to the KDIGO classification
  5. Patients undergoing plasmapheresis, extracorporeal membrane oxygenation (ECMO), extracorporeal carbon dioxide removal (ECCO2R)
  6. Patients who, in the opinion of the investigator, are not expected to survive 72 hours since enrolment
  7. A history of nephrolithiasis or de novo nephrolithiasis
  8. Patient qualified to a protocol for the avoidance of futile therapy
  9. Pregnancy
  10. Sarcoidosis
  11. Risk of impaired intestinal absorption caused by the critical illness, associated with impaired peristalsis and delayed gastric emptying, constipation, diarrhoea, shock-induced intestinal hypoperfusion, hyperhydration with resulting intestinal oedema following fluid resuscitation, intestinal flora disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Interventional Arm

    a single administration of 750,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF

    Drug: Vitamin D3 - 750 000 IU

  • Active comparator
    Control Arm

    a single administration of 500,000 IU of vitamin D3 via the enteral route (through a gastric tube) in ICU patients with severe vitamin D3 deficiency (measured plasma 25(OH)D3 levels ≤12.5 ng/ml) undergoing continuous renal replacement therapy with CVVHDF or CVVHF

    Drug: Vitamin D3 - 500 000 IU

Interventions

  • DrugVitamin D3 - 750 000 IU

    a single administration of 750,000 IU of vitamin D3

  • DrugVitamin D3 - 500 000 IU

    a single administration of 500,000 IU of vitamin D3

06

What researchers measure

Primary outcomes

  1. Supplementation

    To evaluate and compare the effects of two different supplementation doses of vitamin D3 (25(OH)D3) - 500,000 IU or 750,000 IU administered as one enteral dose - on plasma levels of 25(OH)D3 in ICU patients undergoing continuous renal replacement therapy and diagnosed with severe vitamin D3 deficiency

    Time frame: 7 days

Secondary outcomes

  1. Mortality

    To evaluate and compare the effects of two different supplementation doses of vitamin D3 on mortality in ICU patients undergoing continuous renal replacement therapy

    Time frame: 90 days

  2. ICU treatment duration

    To evaluate and compare the effects of two different supplementation doses of vitamin D3 on ICU treatment duration in patients undergoing continuous renal replacement therapy

    Time frame: 90 days

  3. SOFA

    To evaluate and compare the effects of two different supplementation doses of vitamin D3 on Sequential Organ Failure Assessment (SOFA) scores in ICU patients undergoing continuous renal replacement therapy

    Time frame: 90 days

  4. Catecholamines

    To evaluate and compare the effects of two different supplementation doses of vitamin D3 on the duration of catecholamine administration in ICU patients undergoing continuous renal replacement therapy

    Time frame: 90 days

  5. CRRT

    To evaluate the relationship between the length of CRRT use in hours from the time of study drug administration to the beginning of visit 4 and serum vitamin D3 levels in both study arms

    Time frame: 7 days

  6. GRV

    To assess the relationship between total gastric residual volume (GRV) in millilitres from the time of study drug administration to the date of the beginning of visit 3 and serum vitamin D3 levels in both study arms

    Time frame: 7 days

07

Study locations

4 of 4 sites recruiting
  • Uniwersytecki Szpital Kliniczny w Opolu
    Opole, Opolskie 45-401, Poland
    Recruiting
  • 5 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ
    Krakow, Poland
    Recruiting
    • Wojciech Szczeklik, MD, PhD · Contact
  • Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
    Lublin, Poland
    Recruiting
    • Pawel Piwowarczyk, MD, PhD · Contact
  • Samodzielny Publiczny Szpital Kliniczny nr 1 Śląski Uniwersytet Medyczny w Katowicach
    Zabrze, 41-800, Poland
    Recruiting
    • Szymon Bialka, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Jan 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 20, 2022
StartActual
Dec 20, 2022
Primary completionEst.
Jan 1, 2026
CompletionEst.
May 1, 2026
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05657678
Lead sponsor
Uniwersytecki Szpital Kliniczny w Opolu
Responsible party
Tomasz Czarnik, MD PhD (Associate Professor, Uniwersytecki Szpital Kliniczny w Opolu) — Principal investigator
First posted
Dec 20, 2022
Start date
Dec 20, 2022
Primary completion
Jan 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Apr 23, 2024

Study contacts

Tomasz Czarnik, MD, PhD
Contact
tczarnik@mac.com
0048669906333
Tomasz Czarnik, MD, PhD
principal investigator · Uniwersytecki Szpital Kliniczny w Opolu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion